Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.79+0.45%BTC$85,600.00-0.34%ETH$2,697.97-0.63%GOLD$4,192.70+0.86%OIL$89.91+0.54%
Smart Investors Daily
SID Premium
EV

NYSE · EVMN

Evommune, Inc.

Healthcare · Biotechnology

$6.65

Down-$0.15 (-2.26%)

Updated Oct 6, 2026, 6:55 PM

SID Score

2.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
261.72M
P/E ratio
-21.13
Dividend yield
0.00%
52-week range
$6.52 – $29.07
Volume
1.37M
Avg. volume
205.5K

Price performance · EVMN

EVMN price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

EVMN closed at $6.65 after 20 trading sessions, down 49.16% for the selected period.

Last close
$6.65
Period change
-49.16%
Period low
$6.65
Period high
$13.08
Daily close
View OHLC price history
EVMN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$6.86$7.2164$6.52$6.651.37M
Oct 2, 2026$7.25$7.28$6.74$6.921.75M
Oct 1, 2026$8.25$8.30$6.99$7.211.53M
Sep 30, 2026$8.40$8.525$8.11$8.26724.2K
Sep 29, 2026$8.36$8.65$8.11$8.35807.6K
Sep 28, 2026$8.40$8.435$8.12$8.39660.79K
Sep 25, 2026$8.78$8.78$8.33$8.49542.05K
Sep 24, 2026$8.73$8.90$8.25$8.80992.27K
Sep 23, 2026$9.48$9.54$8.69$8.77872.39K
Sep 22, 2026$9.45$9.865$9.3916$9.60573.82K
Sep 21, 2026$9.70$9.70$9.35$9.45603.02K
Sep 18, 2026$9.39$9.75$9.20$9.651.49M
Sep 17, 2026$9.57$9.67$9.35$9.37405.81K
Sep 16, 2026$9.98$9.99$9.3006$9.37568.86K
Sep 15, 2026$10.43$10.43$9.80$9.99520K
Sep 14, 2026$10.49$10.6259$10.31$10.43350.2K
Sep 11, 2026$10.66$10.82$10.50$10.54388.92K
Sep 10, 2026$10.50$11.03$10.31$10.56692.62K
Sep 9, 2026$11.90$12.10$10.3001$10.843.99M
Sep 8, 2026$12.11$13.35$12.01$13.081.24M

Latest EVMN news

The latest Smart Investors Daily articles mentioning EVMN.

Stock researchCompany · Overview

EVMN research

Overview

Company profile and research snapshot.

Company profile

Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$39.33
Implied upside
—
Analysts
—
EVMN recent ratings
DateFirmRatingTarget
Sep 9, 2026Leerink PartnersOutperform—
Sep 9, 2026RBC CapitalOutperform—
Sep 9, 2026HC Wainwright & Co.Neutral—
Aug 26, 2026NeedhamBuy—
Aug 7, 2026RBC CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 23, 2026

Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress

PALO ALTO, Calif. & NEW YORK, September 23, 2026--Evommune, Inc. (NYSE: EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that data from the Phase 2a trial of EVO301 in moderate-to-severe atopic dermatitis (AD) will be presented in a late-breaking oral session at the upcoming European Academy of Dermatology & Venereology (EADV) Congress, taking place in Vienna, Aust

Yahoo · Sep 16, 2026

Evommune (EVMN) Drops EVO756 for Eczema. Can EVO301 Carry the Pipeline?

Evommune, Inc. (NYSE:EVMN) announced on September 8 that EVO756 missed its primary endpoint in a randomized, double-blind, placebo-controlled Phase 2b trial involving 121 adults with moderate-to-severe atopic dermatitis. The primary measure was the percentage change from baseline in Eczema Area and Severity Index, or EASI, at week 12. No tested dose met the primary or […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By